WO2003066088A3 - Protease screening and novel use of proteases - Google Patents

Protease screening and novel use of proteases Download PDF

Info

Publication number
WO2003066088A3
WO2003066088A3 PCT/DE2003/000342 DE0300342W WO03066088A3 WO 2003066088 A3 WO2003066088 A3 WO 2003066088A3 DE 0300342 W DE0300342 W DE 0300342W WO 03066088 A3 WO03066088 A3 WO 03066088A3
Authority
WO
WIPO (PCT)
Prior art keywords
acute
myocardial infarction
thromboses
treatment
proteases
Prior art date
Application number
PCT/DE2003/000342
Other languages
German (de)
French (fr)
Other versions
WO2003066088A2 (en
Inventor
Rudy Susilo
Hans Christian Korting
Hans Guenther Gassen
Martin Hils
Ralf Pasternack
Original Assignee
Trommsdorff Arzneimittel
Rudy Susilo
Hans Christian Korting
Hans Guenther Gassen
Martin Hils
Ralf Pasternack
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trommsdorff Arzneimittel, Rudy Susilo, Hans Christian Korting, Hans Guenther Gassen, Martin Hils, Ralf Pasternack filed Critical Trommsdorff Arzneimittel
Priority to EP03708017A priority Critical patent/EP1471935A2/en
Priority to DE10390318T priority patent/DE10390318D2/en
Priority to AU2003212195A priority patent/AU2003212195A1/en
Publication of WO2003066088A2 publication Critical patent/WO2003066088A2/en
Publication of WO2003066088A3 publication Critical patent/WO2003066088A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a novel use of certain proteases in treatment relating to the healing of wounds, especially the use thereof in fibrinolysis, collagenolysis and plasminogen activation. The invention also relates to screening methods for providing proteases suitable for the above-mentioned uses. The invention further relates to the use of proteases thus obtained, for producing a pharmaceutical composition for using in the healing of wounds, for the prophylaxis and/or treatment of myocardial infarction, thrombosis, venous thromboses, restenosis, hypoxia, ischaemia, coagulation necrosis, inflammation of the blood vessels, acute pulmonary embolism, acute and subacute arterial thromboses, fresh or old clots relating to venous thromboses, deep venous thromboses of the pelvis and the extremities, early thromboses in the region of desobliterated vessels, acute central vessel occlusion in the eye, burns and frostbite, disseminated intravesal coagulation caused by shock, acute arterial occlusion of the extremities, chronic occlusive arteriopathy, and thrombosis of arteriovenous shunts, and for treatment following a myocardial infarction, following a bypass operation, and following ballooning, for thrombolytic treatment of acute myocardial infarction, for the recanalisation of arteriovenous shunts, for the reperfusion of occluded coronary arteries relating to acute myocardial infarction, and following angioplasty with or without stent insertion.
PCT/DE2003/000342 2002-02-06 2003-02-06 Protease screening and novel use of proteases WO2003066088A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03708017A EP1471935A2 (en) 2002-02-06 2003-02-06 Protease screening and novel use of proteases
DE10390318T DE10390318D2 (en) 2002-02-06 2003-02-06 Protease screening and new use of proteases
AU2003212195A AU2003212195A1 (en) 2002-02-06 2003-02-06 Protease screening and novel use of proteases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02002706 2002-02-06
EP02002706.6 2002-02-06
US35781002P 2002-02-21 2002-02-21
US60/357,810 2002-02-21

Publications (2)

Publication Number Publication Date
WO2003066088A2 WO2003066088A2 (en) 2003-08-14
WO2003066088A3 true WO2003066088A3 (en) 2004-04-01

Family

ID=56290377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/000342 WO2003066088A2 (en) 2002-02-06 2003-02-06 Protease screening and novel use of proteases

Country Status (3)

Country Link
EP (1) EP1471935A2 (en)
AU (1) AU2003212195A1 (en)
WO (1) WO2003066088A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808657A (en) 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 Stabilization of vaccines by lyophilization
FR2966734B1 (en) * 2010-10-29 2014-07-18 Max Rombi COMPOSITION COMPRISING AT LEAST ONE PROTEOLYTIC ENZYME FOR ITS USE TO PREVENT THE SYNTHESIS OF TRIGLYCERIDES

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002846A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Enzyme ointment
US4485095A (en) * 1981-08-10 1984-11-27 Kaken Pharmaceutical Co., Ltd. Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
GB2147206A (en) * 1983-09-29 1985-05-09 Ceskoslovenska Akademie Ved Proteolytic enzyme treatment of wounds
EP0296787A1 (en) * 1987-06-22 1988-12-28 JOHNSON & JOHNSON MEDICAL, INC. Absorbent adhesive dressing
US4918008A (en) * 1985-01-18 1990-04-17 Gauri Kailash Kumar Process for the preparation of protein hydrolysate and medicaments containing these hydrolysates
WO1990008555A1 (en) * 1989-01-27 1990-08-09 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
EP0498532A1 (en) * 1991-01-10 1992-08-12 E.R. SQUIBB & SONS, INC. Necrotic tissue debridement powder composition containing a proteolytic enzyme
US5206026A (en) * 1988-05-24 1993-04-27 Sharik Clyde L Instantaneous delivery film
WO1995023614A1 (en) * 1994-03-01 1995-09-08 E.R. Squibb & Sons, Inc. Enzymatic debridement compositions and methods
US5554366A (en) * 1992-04-02 1996-09-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
US20030021775A1 (en) * 2001-07-27 2003-01-30 Ramot University Authority For Applied Research & Industrial Development Ltd. Device for and method of controlled enzymatic removal and retrieval of tissue

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485095A (en) * 1981-08-10 1984-11-27 Kaken Pharmaceutical Co., Ltd. Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
WO1984002846A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Enzyme ointment
GB2147206A (en) * 1983-09-29 1985-05-09 Ceskoslovenska Akademie Ved Proteolytic enzyme treatment of wounds
US4918008A (en) * 1985-01-18 1990-04-17 Gauri Kailash Kumar Process for the preparation of protein hydrolysate and medicaments containing these hydrolysates
EP0296787A1 (en) * 1987-06-22 1988-12-28 JOHNSON & JOHNSON MEDICAL, INC. Absorbent adhesive dressing
US5206026A (en) * 1988-05-24 1993-04-27 Sharik Clyde L Instantaneous delivery film
WO1990008555A1 (en) * 1989-01-27 1990-08-09 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
EP0498532A1 (en) * 1991-01-10 1992-08-12 E.R. SQUIBB & SONS, INC. Necrotic tissue debridement powder composition containing a proteolytic enzyme
US5554366A (en) * 1992-04-02 1996-09-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care method and composition
WO1995023614A1 (en) * 1994-03-01 1995-09-08 E.R. Squibb & Sons, Inc. Enzymatic debridement compositions and methods
US20030021775A1 (en) * 2001-07-27 2003-01-30 Ramot University Authority For Applied Research & Industrial Development Ltd. Device for and method of controlled enzymatic removal and retrieval of tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAZLETT, LINDA D. ET AL: "Proteinase K decreases Pseudomonas aeruginosa adhesion to wounded cornea", EXPERIMENTAL EYE RESEARCH (1992), 55(4), 579-87, XP008024675 *

Also Published As

Publication number Publication date
WO2003066088A2 (en) 2003-08-14
EP1471935A2 (en) 2004-11-03
AU2003212195A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
Aisina et al. Structure and function of plasminogen/plasmin system
US5084274A (en) Inhibition of arterial thrombotic occlusion or thromboembolism
Porte et al. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery
Verhamme et al. The pivotal role of the endothelium in haemostasis and thrombosis
Fenton et al. Thrombin and antithrombotics
Royston Blood-sparing drugs: aprotinin, tranexamic acid, and ε-aminocaproic acid
NO972892L (en) Bicyclic Low Molecular Weight Thrombin Inhibitors
Idell et al. Fibrin turnover in lung inflammation and neoplasia
Cole et al. Ancrod: a practical alternative to heparin
Urano et al. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity
WO2003066088A3 (en) Protease screening and novel use of proteases
Cheng et al. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom
Morrissey Polyphosphate multi‐tasks
EP1509541A4 (en) Novel recombinant anticoagulant proteins
JPS6475431A (en) Novel protease preparation
WO2001057193A3 (en) Protein c derivatives
Becker Thrombin antagonists and antiplatelet agents
ATE498305T1 (en) PREVENTING AND TREATING DISEASES RELATED TO BLOOD CLOTTING
SI22865A (en) Peptide uroaktivin as activator of enzyme urokinase
Bell Thrombolytic therapy: Agents, indications, and laboratory monitoring
Nikonov et al. Biological activity and pharmacological properties of anticoagulant complex (hirudin, plasma kallikrein inhibitor, prostaglandin) from Hirudo medicinalis
Shebuski Emerging drug discovery targets in thrombosis and coagulation
Wang et al. Thrombin stimulates mitogenesis in pig cerebrovascular smooth muscle cells involving activation of pro-matrix metalloproteinase-2
Sadeghi et al. Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding
WO2003075848A3 (en) Inhibitors for use in hemostasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003708017

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003708017

Country of ref document: EP

REF Corresponds to

Ref document number: 10390318

Country of ref document: DE

Date of ref document: 20050105

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10390318

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003708017

Country of ref document: EP